Microcin B17 is a 3.1-kDa bactericidal peptide; the putative target of this antibiotic is DNA gyrase. Microcin B17 has no detectable effect on gyrase-catalysed DNA supercoiling or relaxation activities in vitro and is unable to stabilise DNA cleavage in the absence of nucleotides. However, in the presence of ATP, or the non-hydrolysable analogue 5
Introduction
Microcins are a class of low molecular mass antibiotics produced and excreted by Enterobactericeae. 1 Microcin B17 (MccB17; Figure 1 (a)) is a 3.1-kDa post-translationally modi®ed peptide that is produced by Escherichia coli containing the plasmid-borne MccB17 operon. 2 This operon contains the genes encoding the precursor polypeptide of MccB17, mcbA, the MccB17 synthetase, mcbBCD, which transforms cysteine and serine residues of McbA into thiazoles and oxazoles, as well as mcbE, mcbF and mcbG which are required for export of the mature antibiotic and immunity of the producing cells. 3 The effects of MccB17 on sensitive E. coli include growth inhibition, a rapid decline in DNA replication, and induction of the SOS response. 4 Furthermore, MccB17 induces doublestrand cleavage of plasmid DNA when incubated with cell-free extracts. 5 In screens for MccB17-resistant E. coli mutants, two independent clones were isolated that had the same mutation, an AT-GC transition at position 2251 of the B subunit of DNA gyrase. 5 This mutation results in the substitution of the tryptophan residue at position 751 by an arginine and confers resistance to MccB17-induced DNA cleavage in extracts. These observations suggested that the primary target for MccB17 is DNA gyrase, although the mode of action is unknown.
DNA gyrase is a prokaryotic type II topoisomerase. 6, 7 Its main, and unique, function is negative supercoiling of closed-circular DNA, which requires the free energy of ATP hydrolysis. The enzyme consists of two proteins, GyrA and GyrB, and the active enzyme is an A 2 B 2 tetramer. Gyrase introduces supercoils by wrapping a segment of DNA ($130 bp) around itself, cleaving the DNA in both strands, passing another segment through the break and then resealing the DNA. This reaction (negative supercoiling) results in the reduction of the linking number of the DNA by 2. The GyrA subunit (Figure 1(b) ) is responsible for DNA wrapping and contains Tyr122, the active- site residue that forms a covalent phosphotyrosine link with DNA during the cleavage step. GyrB contains the site of ATP hydrolysis as well as thè`c lamp'' which captures the piece of DNA to be passed through the break. Each subunit of gyrase can be divided into two domains (Figure 1(b) ). The crystal structures of the N-terminal 43-kDa domain of GyrB and an N-terminal 59-kDa fragment of GyrA have been solved. 8, 9 Structures of the 33-kDa C-terminal domain of GyrA and the 47-kDa C-terminal domain of GyrB have not yet been determined, however the structure of a 92-kDa fragment of yeast topoisomerase II (topo II) has been solved in two conformations. 10, 11 This fragment of topo II is homologous to the 59-kDa region of GyrA plus the 47-kDa C-terminal region of GyrB, allowing the structure of the 47-kDa domain of GyrB to be inferred.
Inhibitors of gyrase include the coumarin and quinolone antibacterials, and the bacterial toxin CcdB. 12 Some mutations that afford resistance to these inhibitors are indicated in Figure 1 (b). Coumarins bind to GyrB and competitively inhibit ATP hydrolysis. Quinolones, such as the widely used cipro¯oxacin (CFX; Figure 1 (a)), are thought to work by binding to a complex of gyrase (A 2 B 2 ) and DNA, producing a``cleavage complex''. This interaction leads to trapping of the intermediate in which the active-site tyrosine (Tyr122) of each GyrA subunit is covalently attached to the 5 H -phosphate, producing a double-strand break in the DNA. The initial binding of the drug is rapid and correlates with inhibition of supercoiling; conversion to the second complex, with the DNA stabilised in the cleaved form, is slower. 13 Quinolones are thought to interact with GyrA within the boundaries of a relatively small and well-de®ned region (amino acid residues 67 to 106; Figure 1(b) ), known as the``quinolone-resistance-determining region'' (QRDR). 14 CcdB is a 101-residue polypeptide produced by the E. coli F plasmid. CcdB forms a complex with gyrase and DNA and normally stabilises a cleavage complex only in the presence of ATP. 15 This process is slow, apparently requiring many rounds of ATP hydrolysis to reach completion. The present model for the CcdB mode of action suggests that the protein initially binds to GyrA and then, during ATP hydrolysis, the complex is slowly converted to a second form in which the cleaved-DNA complex is stabilised. 16 The details of how this occurs are unclear at present, but the cytotoxic effects of CcdB may have useful applications in biotechnology and have been used in recombinational cloning. 17 In this paper we explore the effects of MccB17 on DNA gyrase. The signi®cant amount of knowledge about the mode of action of other DNA gyrase inhibitors suggests that a comparison with MccB17 may provide an understanding of the mechanism of action of this antibacterial agent. In addition, it is likely that studies of the MccB17-gyrase interaction will reveal new information about the mode of action of DNA gyrase. To this end, in vitro assays were used to study the characteristics of the interaction between MccB17 and gyrase and to compare these activities with those of other gyrase inhibitors.
Results
MccB17 does not affect the supercoiling or relaxation reactions of DNA gyrase DNA gyrase introduces negative DNA supercoils in the presence of ATP and relaxes them in its absence. 6, 7 MccB17 does not detectably affect either of these reactions (data not shown), in marked contrast to quinolones and other gyrase inhibitors. 12 In addition, pre-incubation of MccB17 with GyrA and GyrB, either individually or as a complex, does not affect subsequent supercoiling reactions. These results suggest that the ability of MccB17 to trap the enzyme in a covalent complex with cleaved DNA (see below) may occur with low ef®ciency and require multiple catalytic cycles. Furthermore, we have been unable to observe any signi®cant effect of MccB17 on both the DNA-dependent and DNAindependent ATPase activities of gyrase.
MccB17 induces gyrase-dependent formation of a cleavage complex
During its catalytic cycle, gyrase produces a double-strand break in the DNA substrate. This break is normally transient but can be trapped by quinolone drugs, CcdB, or Ca 2 , resulting in a stable complex known as the cleavage complex. When MccB17 was titrated into a mixture of gyrase, relaxed closed-circular DNA, and ATP, followed by incubation for 90 minutes at 37 C, cleaved DNA was produced ( Figure 2 ). Cipro¯oxacin also produces cleaved DNA under the same conditions. In this experiment the inhibitor (MccB17 or CFX) was added last, so the relaxed DNA substrate was supercoiled by DNA gyrase prior to the addition of inhibitor. The experiment was performed in this manner because MccB17-induction of the cleavage complex is much slower than that of CFX and is not detectable until the DNA has become supercoiled (data not shown), whereas CFX blocks supercoiling activity immediately. Allowing the DNA to become supercoiled before adding inhibitor ensured that the DNA was in the same topological state regardless of which inhibitor was being tested. If gyrase rather than inhibitor was added last, the results were the same as shown except that the substrate DNA remained relaxed in the presence of CFX and became supercoiled in the presence of MccB17. In addition, if supercoiled DNA is used as a substrate for this assay, similar levels of DNA cleavage are produced by MccB17 (data not shown).
DNA cleavage experiments carried out in the presence of ATP were compared to similar experiments performed in the absence of nucleotide or in the presence of ADPNP, a non-hydrolysable analogue of ATP ( Figure 3 ). Cipro¯oxacin induced the accumulation of cleaved DNA under all three conditions. A similar experiment with MccB17 demonstrated that in the presence of ATP, the IC 50 for MccB17 is 0.9 mM, compared to 0.3 mM for cipro¯oxacin and the level of DNA cleavage was lower than that induced by cipro¯oxacin. In the presence of ADPNP, the IC 50 for MccB17 increased signi®cantly, to 12.0 mM, a difference not observed with cipro¯oxacin. Furthermore, little or no DNA cleavage was detected in the absence of nucleotide when up to 64 mM MccB17 was added to the reaction ( Figure 3) . If supercoiled or linear pBR322 DNA was used as substrate, nucleotide-dependent cleavage in the presence of MccB17 was also observed (data not shown). These results suggest that MccB17, like cipro¯oxacin, stabilises an enzyme-cleaved DNA complex, but is only able to do so in the presence of nucleotide. One explanation for the different levels of maximum cleavage in the presence of the two inhibitors ( Figure 3 ) is that MccB17 is unable to shift the cleavage-religation equilibrium as far towards the cleaved form compared to CFX.
Cleavage kinetics of MccB17-induced cleavage compared to ciprofloxacin
The kinetics of MccB17 and CFX-induced DNA cleavage by gyrase were compared by taking samples from cleavage reactions at different times ( Figure 4 ). With CFX, 50 % of the maximum cleavage was observed in less than one minute in the presence of ATP, but without nucleotide or in the presence of ADPNP, cleavage was much slower, taking seven to nine minutes to reach 50 %. For MccB17 the time to reach 50 % of the maximal cleavage was approximately three minutes in the presence of ATP and $11 minutes in the presence of ADPNP; again no signi®cant cleavage was apparent in the absence of nucleotide. The cleavage specificity of MccB17 is similar to that of Ca 2 Linear pBR322 DNA incubated with excess gyrase in the presence of a quinolone drug or Ca 2 is cleaved at several sites. 18 Analysis of the cleaved DNA on an agarose gel reveals several bands of varying sizes, thus producing a``®ngerprint'' speci®c to the cleavage-stabilising agent. Two of the major bands observed by using this method correspond to cleavage of pBR322 at position 990, a preferred cleavage site for DNA gyrase in the presence of oxolinic acid and other quinolones. 19 As shown in Figure 5 , CFX-and Ca The gyrase-MccB17 complex on DNA blocks the passage of DNA polymerase
In the presence of quinolone drugs, DNA gyrase forms a cleavage complex with DNA. This complex acts as a barrier to DNA polymerase, resulting in blocking of replication at the site of gyrase binding. 20 In an experiment similar to that carried out previously, replication by bacteriophage T7 polymerase of a DNA substrate containing the 990 site was investigated. Uninhibited replication produces a full-length product of 275 bases. In the presence of CFX and gyrase, a truncated product is generated, indicating that the passage of the replication proteins along the template has been blocked, presumably by the covalently bound protein-DNA complex. This truncated product is also produced in the presence of MccB17 and gyrase (Figure 6 ), demonstrating that MccB17, like CFX, blocks replication in the presence of gyrase suggesting similar bacteriostatic mechanisms. Furthermore, the major blocking site on the substrate DNA is the same for both CFX and MccB17. We have also found that the MccB17-resistant mutant GyrB(W751R) shows no evidence of replication blocking (results not shown).
Effects of mutations in GyrA and GyrB on MccB17 action
A number of gyrase mutants were tested in a MccB17 cleavage assay: GyrB(W751R), a mutant discovered in MccB17-resistant E. coli cells, GyrB(K447E) and GyrA(S83W), both quinoloneresistant mutants, [21] [22] [23] and GyrA(R462C), a mutant with resistance to CcdB. 24 As, at present, there is no crystal structure for the 47-kDa Cterminal region of GyrB, the location of residues GyrB751 and GyrB447 can only be inferred using the structure of the 92-kDa fragment of yeast topo II, which is homologous to the Nterminal 59-kDa domain of GyrA and the 47-kDa C-terminal domain of GyrB. 9, 10 The sites of the mutated residues in the homologous regions of topo II are shown in Figure 7 . To perform this experiment, MccB17 was titrated into a mixture containing relaxed pBR322 and gyrase. To normalise the activity between the wild-type gyrase and the mutant proteins, control reactions with Ca 2 were performed with each mutant to serve as internal references. Each mutant was used at a concentration where it is functional and produces detectable DNA cleavage equal to or greater than wild-type when exposed to Ca 2 , within a range of 80-220 nM. (Gyr-A(S83W) is resistant to Ca 2 -induced cleavage; 25 in this case a concentration ten times that required to give supercoiling activity equivalent to wild-type was used.) Mutants were then tested for DNA cleavage with MccB17 (0-32 mM; Figure 8 ). These in vitro results con®rm that GyrB(W751R) is resistant to MccB17; cleavage is detectable at MccB17 concentrations as low as 0.5 mM for wild-type gyrase but little or no cleavage is detectable at up to 32 mM for the mutant. This corresponds to a reduction in MccB17 potency by at least 64-fold, which compares with an eight-to tenfold resistance originally observed in the in vivo assays of the W751R mutant. 5 (IC 50 values were not determined, as the level of cleavage with the mutant was very low.) The quinolone-resistant mutants GyrB(K447E) and GyrA(S83W) also exhibit signi®cant levels of resistance to MccB17. In these mutants, cleaved DNA is detectable, but only at higher MccB17 concentrations than are required to detect cleavage for the wild-type enzyme. In addition, the ®nal level of cleaved DNA observed with these mutants is two-to threefold lower. The CcdB-resistant mutant GyrA(R462C) exhibits cleavage levels comparable to those observed with wild-type protein.
Discussion
Several antibacterial compounds that target DNA gyrase, whether synthetic (e.g. quinolones) or produced by bacteria (e.g. CcdB), work by stabilising gyrase and DNA in a complex in which the DNA is cleaved across both strands. The release of cleaved DNA is thought to activate the cell-death pathway. 26 The antibiotic MccB17 may function in a similar fashion, and Table 1 summarises the properties of MccB17 revealed in this study and compares them to those of well-known gyrase inhibitors, quinolones, CcdB, and Ca 2 . This study provides in vitro evidence that DNA gyrase is a target of MccB17. In the presence of ATP, MccB17 induces gyrase-dependent DNA clea- They result from cleavage at the 990 site, the favoured site in pBR322 for gyrase cleavage in the presence of quinolones. 19 vage in a reaction reminiscent of quinolone-stabilised DNA cleavage. Replication blocking experiments demonstrated that MccB17, like CFX, inhibits the progress of a replication fork in the presence of gyrase. MccB17 has no detectable effect on the ATPase activity of gyrase or on the supercoiling or relaxation reactions of the enzyme. Quinolones have a pronounced effect on the kinetics of the DNA-dependent ATPase reaction of gyrase, but have no effect on the DNA-independent reaction; 13 similar results have been obtained with CcdB. 16 Coumarins completely abolish ATPase activity. 12 These results suggest that some aspects of the action of MccB17 are distinct from those of Interaction of Microcin B17 with DNA Gyrase other inhibitors. The lack of any observable supercoiling inhibition may be due to the inef®cient action of MccB17. In such circumstances, supercoiling can occur prior to the reaction producing the cleaved complex. A similar situation is observed in reactions with CcdB, in which a number of turnovers must occur before the cleavable complex can be detected. 16, 27 The addition of quinolone to a gyrase-DNA complex leads to stabilisation of an altered conformation of the enzyme, associated with inhibition of supercoiling. This altered conformation is thought to involve the 47-kDa C-terminal domain of GyrB, as this region is protected from proteolysis by trypsin in the presence of quinolone but not in its absence. 28 This initial conformation is followed by conversion to a second conformation, that in which the DNA is cleaved; formation of the cleavage complex is relatively slow. 13 The fact that MccB17 is able to stabilise a cleaved complex on a similar time-scale to CFX (Figure 4 ) but is unable to inhibit supercoiling, suggests that MccB17 does not stabilise the initial conformation. This is also supported by the fact that MccB17-gyrase-DNA complexes do not protect the 47-kDa C terminus of GyrB from digestion by trypsin (data not shown).
MccB17 is less potent than CFX as measured by IC 50 values (0.9 mM versus 0.3 mM, respectively, in the presence of ATP). The amount of cleaved complex formed in the presence of MccB17 is signi®-cantly less than with the quinolone (Figures 3 and  4) . The stabilisation of the cleavage complex is likely to be due to a change in the cleavage-religation equilibrium such that the cleaved form is favoured, i.e. through a slower rate of DNA religation. It seems likely therefore, that the reduced amount of cleaved DNA seen in the presence of MccB17 compared to CFX is due to an alteration in the DNA cleavage-religation equilibrium such that it lies further towards the religation side in the presence of MccB17.
MccB17 exerts some effects on DNA gyrase that are different from those of quinolones. Quinoloneinduced cleavage is independent of the presence of nucleotides, whereas cleavage stabilised by MccB17 requires the presence of ATP or the nonhydrolysable analogue ADPNP. This observation is reminiscent of the mechanism of action of CcdB; CcdB also requires ATP hydrolysis in order to stabilise a cleavage complex. However, under most conditions, CcdB is unable to stabilise a cleavage complex in the presence of ADPNP. 29 One interpretation of these observations could be that gyrase only associates with MccB17 after the conformational change induced by binding of ATP (or an analogue) has occurred.
A comparison of the pattern of fragments produced following cleavage stimulated by MccB17, CFX, or Ca 2 suggests that the cleavage speci®city of gyrase in the presence of MccB17 most closely resembles that of Ca 2 . Quinolones are thought to direct the formation of cleavage complexes to preferred sites, 30 perhaps due to interactions of the drugs with DNA; quinolone drugs have been shown to be able to bind weakly to DNA alone. 31 ± 34 There is currently no evidence for the interaction of MccB17 with DNA. One possibility therefore is that the cleavage patterns observed in the presence of Ca 2 and MccB17 re¯ect the formation of gyrase-DNA complexes at positions that are not in¯u-enced by the inhibitor. Crystal structure of the 92-kDa fragment of yeast topoisomerase II. 10 The residues highlighted are analogues of DNA gyrase residues: GyrB447 (red), GyrB751 (green), GyrA83 (yellow), and GyrA462 (blue).
Analysis of gyrase mutants reveals that mutations that confer quinolone resistance can also provide protection from MccB17. This result suggests that the MccB17-binding region on gyrase may overlap with the quinolone-binding region. In contrast, GyrA(R462C), the only CcdB-resistant mutant yet isolated, is not resistant to MccB17. Therefore, despite the similarity in the features of inhibition, the binding loci of CcdB and MccB17 are likely to be distinct. Trp751 in GyrB is an important residue in the MccB17-gyrase interaction and could represent part of a binding site for MccB17, possibly consisting of a hydrophobic interaction of the Trp indole system with the apolar MccB17 molecule. Topoisomerase IV, another type II topoisomerase in E. coli, has an arginine at position 575 of ParE (equivalent to 751 in GyrB) and does not exhibit sensitivity to MccB17 (M.K.
Wall, personal communication). The fact that
Trp751 appears a long way from the QRDR, based on the crystal structure of topo II, does not preclude the possibility of overlap of MccB17 and quinolone binding sites. It is known that residues within GyrB are required for DNA cleavage 35 and conformational changes are likely to occur in GyrB during the enzymic reaction to bring these regions closer together. 10, 11 We have demonstrated that MccB17 can induce gyrase-dependent DNA cleavage, and we have begun to characterise this interaction. These results provide a foundation for subsequent studies of the structure-activity relationships of wild-type and mutant MccB17s as DNA gyrase poisons. Furthermore, a comparison of the modes of action of four gyrase inhibitors could be useful in the elucidation of mechanism of activity for each of these toxins Figure 8 . DNA cleavage by gyrase mutants. The reactions contained 3.4 nM pBR322 and increasing amounts of MccB17, and wild-type and mutant gyrases as indicated. Gyrase concentrations were in the range 80-220 nM. The amounts used were those that produced similar cleavage activities with 4 mM Ca 2 except for W83, which is resistant to Ca 2 cleavage. 25 In this instance the concentration of W83 tetramer used was ten times that required to give equivalent supercoiling activity to the wild-type enzyme. n.c., nickedcircular DNA; lin., linear DNA; c.c., closed circular DNA; r, reaction mix with no enzyme.
Interaction of Microcin B17 with DNA Gyrase and may shed light on unresolved questions in the DNA gyrase mechanism.
Materials and Methods
Proteins, DNA and drugs GyrA and GyrB (mutant and wild-type proteins) were made as described by Maxwell & Howells. 36 GyrA and supercoiled and relaxed plasmid pBR322 DNA were gifts from Mrs A.J. Howells (University of Leicester). Plasmid pAGW751R, encoding GyrB(W751R), plasmid pAGD426N, encoding GyrB(D426N), and plasmid pJGH1, encoding GyrB(K447E), were made using the Quikchange mutagenesis kit (Stratagene) and plasmid pAG111. 37 GyrA(S83W) was a gift from Dr C.J.R. Willmott (University of Leicester) and GyrA(R462C) was a gift from Dr N.L. Williams (University of Leicester). MccB17 was produced as described by Sinha Roy; 38 stocks for gyrase assays were prepared in DMSO and undissolved material was removed by centrifugation. The concentration of MccB17 was determined by drying aliquots, resuspending them in 50 % acetonitrile, and measuring the absorbance at 254 nm, using an extinction coef®cient of 39,216 M À1 cm
À1
. Cipro¯oxacin (Bayer) was dissolved in water.
DNA gyrase assays
DNA supercoiling and relaxation reactions were carried out as described by Reece & Maxwell 39 except that the incubation temperature was 37 C and reactions were incubated for up to two hours. MccB17 and cipro¯oxa-cin-induced DNA cleavage reactions were carried out using a similar method to that described elsewhere. 39 GyrA and GyrB were added to reactions that contained 35 mM Tris-HCl (pH 7.5), 24 mM KCl, 4 mM MgCl 2, 1.8 mM spermidine, 5 mM DTT, 6.5 % (w/v) glycerol, 0.36 mg/ml Bovine serum albumin (BSA), 9 mg/ml tRNA, 2 mM ATP or ADPNP and 3.4 nM pBR322 DNA. CFX or MccB17 were present at varying concentrations and concentrations of DMSO were kept constant throughout. Reaction mixtures were incubated at 37 C for 90 minutes. SDS (0.2 %) and proteinase K (0.1 mg/ ml) were added and the reactions incubated for a further 30 minutes at 37 C. Reactions were stopped by the addition of an equal volume of chloroform:isoamyl alcohol (24:1) and a half volume of 40 % (w/v) sucrose in 0.1 M Tris-HCl (pH 8.0), 0.1 M EDTA, and 0.5 mg/ml bromophenol blue, and the mixtures were then vortexed and centrifuged for one minute at 13,000 rpm. The DNA-containing aqueous phase was loaded onto 1 % (w/v) agarose gels containing 1 mg/ml ethidium bromide and run at 110 V for approximately two hours. Cleavage time-courses were performed by using an identical method except that samples were removed at various times.
Conditions for cleavage speci®city reactions were the same as for the cleavage reactions described above except that linear pBR322 was used and at a threefold higher concentration. The DNA was run on 1.2 % agarose gels at 30 V for 16 hours. ATPase reactions were performed using an enzyme-linked assay as described by Ali et al. 40 
Replication assays
Replication reactions (30 ml) were performed as described by Wentzell & Maxwell 20 in 40 mM Tris-HCl (pH 7.5), 50 mM NaCl, 10 mM MgCl 2 , 2 mM DTT, 0.1 mM EDTA, 100 mg/ml BSA and 2.5 % (v/v) DMSO. For standard reactions, the template DNA (14 nM) was pre-incubated with buffer, a twofold molar excess of the appropriate primer, DNA gyrase and quinolone for one hour at 25 C. This was followed by the addition of 200 mM each of dATP, dCTP, dTTP and dGTP, 80 nM T7 DNA polymerase and 50 nM T7 4B helicase, followed by incubation at 37 C for ten minutes. Reactions were stopped with 20 mM EDTA (pH 8.0) and the DNA was precipitated with ethanol. The samples were resuspended in 98 % (v/v) formamide, 10 mM EDTA (pH 8.0), 0.025 % (w/ v) xylene cyanol FF and 0.025 % (w/v) bromophenol blue and analysed by electrophoresis through a 30 cm Â 40 cm denaturing 6 % (w/v) polyacrylamide (19:1) gel that contained 7 M urea and 30 % (v/v) formamide in TBE buffer. Gels were dried and subjected to autoradiography overnight. 
